Product Description: Belrestotug (EOS-448) is an antagonistic anti-TIGIT (VSIG9, VSTM3) human immunoglobulin G1 kappa (hIgG1 kappa) antibody. Belrestotug shows antineoplastic activity[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]International Nonproprietary Names for Pharmaceutical Substances (INN). WHO Drug Information, Vol. 36, No. 2, 2022.
CAS Number: 2574438-65-4
Molecular Weight: N/A
Research Area: Cancer
Solubility: H2O
Target: Others